Data from a dose-ranging Phase 1 study of a respiratory syncytial virus vaccine candidate from...

|By:, SA News Editor

Data from a dose-ranging Phase 1 study of a respiratory syncytial virus vaccine candidate from Novavax (NVAX) shows that "all subject groups receiving … the [treatment] exhibited antibody responses against RSV at 28 and 56 days post-immunization." Shares +5.7% premarket. (PR)